STAT Plus In another setback in the lucrative lung cancer market BristolMyers Squibb $BMY is withdrawing its application with the FDA to use its cancer immunotherapy blockbuster Opdivo. httpsbuff.ly2WgNUooÂ

STAT Plus: In another setback in the lucrative lung cancer market, Bristol-Myers Squibb ($BMY) is withdrawing its application with the FDA to use its cancer immunotherapy blockbuster, Opdivo. https://buff.ly/2WgNUoo 

07:04 EST 24 Jan 2019 | STAT

STAT Plus: In another setback in the lucrative lung cancer market, Bristol-Myers Squibb ($BMY) is withdrawing its application with the FDA to use its cancer immunotherapy blockbuster, Opdivo. https://buff.ly/2WgNUoo 

More From BioPortfolio on "STAT Plus: In another setback in the lucrative lung cancer market, Bristol-Myers Squibb ($BMY) is withdrawing its application with the FDA to use its cancer immunotherapy blockbuster, Opdivo. https://buff.ly/2WgNUoo "